Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz
Mipomersen lowers cholesterol but not without liver side effects.
10:56AM 11/17/09
InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz
Safety monitors force change to mid-stage study of ITMN-191
09:11AM 11/17/09
Doc Offers Top Hep C Drug Picks: BioBuzz
Vertex, InterMune, Pharmasset get positive reviews after recent Hep C meeting.
01:54PM 11/09/09
Biotech Calendar: Key Dates for November
Your quick-and-dirty guide to key dates and events for biotech investors during November.
07:12AM 11/02/09
Biotech Calendar: Key Dates and Events
A quick and dirty guide to important biotech events for October.
09:55AM 09/30/09
Premarket Roundup: Starent Networks, Pharmasset
Premarket roundup: Starent would gain from an Apple-Verizon contract, Pharmasset upgraded
09:23AM 09/08/09
Robert W. Baird analyst upgrades Pharmasset, citing potential for developing hepatitis C drug
08:46AM 09/08/09
Sequenom Fallout Hits Hedge Funds
Investors are selling biotech stocks owned by two hedge funds that took highly concentrated positions in Sequenom on fears that they may be forced to liquidate their other holdings.
02:47PM 04/30/09
Flu-Related Plays to Consider (Biotech Select $)
One model portfolio name may benefit from the current outbreak. Also, updates from last week's liver disease conference.
12:42PM 04/27/09
Hepatitis C Updates From EASL Liver Confab
Here are some of the hightlights from the European Association of the Study of Liver Disease conference.
09:43AM 04/27/09
Anadys Stock Falls on Hep C Data
Anadys releases new data on its lead hepatitis C drug demonstrating the drug's antiviral activity at three different doses.
12:00PM 04/23/09
Pharmasset Cancels Hepatitis Drug Development
Pharmasset ends development of lead drug candidate over concerns for hepatitis B patients
08:23AM 04/20/09
New Vertex CEO: Hep C Trials on Track
As Vertex reports quarterly results, new CEO Matt Emmens says all patients in three pivotal studies have finished treatment with the company's experimental hepatitis C drug telaprevir.
04:16PM 04/16/09
Anadys Tries to Tempt Suitors With Hep C Data
Anadys has been sharing still-confidential clinical data on its lead hepatitis C drug in the hopes of attracting a rich partner.
01:23PM 04/06/09



Connect with TheStreet